Lisaftoclax induced responses in patients with a variety of relapsed/refractory malignancies, including NHL and CLL. In the study, 11 patients with relapsed/refractory diffuse LBCL were infused with anbal-cel. The ORR was 96%, including 92% at the level of VGPR, and the MRD negativity rate was 62%... Among 37 evaluable patients, the ORR was 78%, and 27 patients had a VGPR or better... A phase III trial of magrolimab plus azacitidine versus standard of care in TP53-mutated AML is currently ongoing. Of 23 patients, three achieved complete remission and 15 achieved complete remission with incomplete hematological recovery. Epcoritamab is a subcutaneous CD3/CD20 bispecific antibody that induces anti-tumor activity across B-cell NHL subtypes. The phase III GALLIUM study confirmed obinutuzumab plus chemotherapy as a standard of care for first-line follicular lymphoma